Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Gefapixant in two randomised dose-escalation studies in chronic cough

Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal 2020; DOI: 10.1183/13993003.01615-2019
Jaclyn A. Smith
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael M. Kitt
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Butera
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Smith
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuping Li
3GetStat Solutions, LLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi Jin Xu
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberley Holt
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shilpi Sen
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mandel R. Sher
4Center for Cough, Largo, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony P. Ford
2Merck & Co., Inc., Kenilworth, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background Gefapixant has previously demonstrated efficacy in the treatment refractory chronic cough at a high, daily dose.

Objectives The current investigations explore efficacy and tolerability of gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough using a dose escalation approach.

Materials and methods Two randomised, double-blind, placebo-controlled, crossover, dose-escalation studies recruited participants with refractory chronic cough. Patients were assigned to receive ascending doses of gefapixant (study 1: 50–200 mg, study 2: 7.5–50 mg) or placebo for 16 days, then crossed-over after washout. The primary endpoint was awake cough frequency assessed using a 24 h ambulatory cough monitor at baseline and on day 4 of each dose. Patient reported outcomes included a cough severity visual analogue scale (VAS) and Cough Severity Diary (CSD).

Results In clinical studies, gefapixant doses ≥30 mg produced maximal improvements in cough frequency compared with placebo (p<0.05); reported cough severity measures improved at similar doses. Taste disturbance exhibited a different relationship with dose, apparently maximal at doses ≥150 mg.

Conclusions P2X3 antagonism with gefapixant demonstrates anti-tussive efficacy and improved tolerability at lower doses than previously investigated. Longer duration studies are warranted.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr Smith reports grants and personal fees from Merck Inc, during the conduct of the study; grants and personal fees from Glaxosmithkline, grants and personal fees from NeRRe Pharmaceuticals, grants and personal fees from Menlo, grants and personal fees from Bayer, personal fees from Boehringer Ingleheim, personal fees from Genentech, personal fees from Neomed, non-financial support from Vitalograph, personal fees from Cheisi, grants and personal fees from Afferent, personal fees from Bellus, grants and personal fees from Axalbion, personal fees from AstraZeneca, outside the submitted work; In addition, Dr Smith has a patent A method for generating output data licensed.

Conflict of interest: Dr Kitt reports other from Merck/Afferent, during the conduct of the study; other from Merck/Afferent, outside the submitted work.

Conflict of interest: Dr Butera reports other from Afferent Pharmaceuticals, Inc., during the conduct of the study; other from Afferent Pharmaceuticals, Inc., outside the submitted work; and I was an employee of Afferent Pharmaceuticals, Inc..

Conflict of interest: Mr. Smith reports personal fees from Afferent Pharmaceuticals, during the conduct of the study

Conflict of interest: Dr Li reports personal fees from Afferent/Merck &amp; Co., Inc, during the conduct of the study.

Conflict of interest: Dr Xu has nothing to disclose.

Conflict of interest: Ms. Holt has nothing to disclose.

Conflict of interest: Dr Sen has nothing to disclose.

Conflict of interest: Dr sher reports personal fees from Afferent, personal fees from Merck, during the conduct of the study; and Consultant to Bellus, Bayer, NeRRe with clinical studies with Menlo and NeRRe.

Conflict of interest: Dr Ford has nothing to disclose.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received August 13, 2019.
  • Accepted December 19, 2019.
  • Copyright ©ERS 2020
PreviousNext
Back to top
View this article with LENS
Vol 59 Issue 6 Table of Contents
European Respiratory Journal: 59 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gefapixant in two randomised dose-escalation studies in chronic cough
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Gefapixant in two randomised dose-escalation studies in chronic cough
Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal Jan 2020, 1901615; DOI: 10.1183/13993003.01615-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Gefapixant in two randomised dose-escalation studies in chronic cough
Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal Jan 2020, 1901615; DOI: 10.1183/13993003.01615-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • Pulmonary pharmacology and therapeutics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • StO2 during weaning from mechanical ventilation
  • Automated quantification of radiological patterns predicts IPF survival
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society